Atrophy of fast myofibers is a common feature in several myopathies but is poorly recapitulated in animal models. Mutations in the gene encoding leiomodin-3 (LMOD3) have been detected in individuals with nemaline myopathy (NM), a common congenital disorder associated with muscle weakness and the presence of rod-like structures (nemaline bodies) in both fast and slow skeletal muscle fibers. To shed light on LMOD3 function in NM, Tian Xu and collaborators generated a mouse mutant in which they disrupted the expression of the LMOD3 gene. These mutants show typical features of NM, including severe muscle weakness, postnatal growth retardation, and nemaline bodies and disorganized sarcomeric structures in the skeletal muscles. Notably, these animals exhibit atrophy specifically in fast myofibers. LMOD3 mutant mice are the first to experimentally model fast-myofiber atrophy, a unique clinical feature of several human myopathies. This mouse mutant can thus be used to further elucidate disease mechanisms and to identify potential targets for therapeutic purposes. Page
Skip Nav Destination
Article navigation
June 2015
Virtual Meeting - Developmental Disorders: From Mechanism to Treatment
A collaboration between the Development and Disease Models & Mechanisms journal teams, this virtual Meeting will unite developmental biologists, human geneticists and clinical researchers to focus on building bridges from bench to clinic. Register your interest and find out more.
High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition
Vitamin B1 is shown to prevent nutrition-induced fatty liver in our current Editor’s choice by Hay Davir and his colleagues, when they use sheep as a large-animal model for studying the disease.
Find out more in an interview with the paper's first authors, Mugagga Kalyesubula and Ramgopal Mopuri.
Upcoming grant deadlines
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on targeting the RAS pathway.
Social media
